Here is the design of a clinical trial:

Official Title: Symptoms of Depression, Stress and Burnout, and Long-term Psychological Impact in Health Care Professionals Exposed to the Novel Coronavirus Disease 2019 Outbreak (HARD-COVID-19 - Health cAre woRkers exposeD to covID-19)

Included conditions:
- Depression
- Burnout, Professional
- Post Traumatic Stress Disorder

Study Armgroups:
- {'label': 'Usual Care', 'type': 'NO_INTERVENTION', 'description': 'Subject from this group are screened positive for psychological distress but they will only receive standard of care.'}
- {'label': 'Eye Movement Desensitization & Reprocessing Group', 'type': 'EXPERIMENTAL', 'description': 'Subject from this group are screened positive for psychological distress. They will receive 12 sessions of Eye Movement Desensitization \\& Reprocessing therapy by a trained therapist over three months in addition to standard of care.', 'interventionNames': ['Behavioral: EMDR']}

Interventions:
- {'type': 'BEHAVIORAL', 'name': 'EMDR', 'description': 'The EMDR therapy is organized in eight different phases, requiring attending multiple sessions, usually 12 separate sessions.', 'armGroupLabels': ['Eye Movement Desensitization & Reprocessing Group']}

Primary Outcomes:
- {'measure': 'Efficacy on symptoms of Post-Traumatic Stress Disorder', 'description': 'This study is investigating three different conditions (PTSD, Depression and Burnout) each assessed with its own primary endpoint. Thus, the trial will have three primary endpoints.\n\nChange over a 6 months period in symptoms of PTSD measured by the Post-Traumatic Stress Disorder Checklist Scale for Diagnostic and Statistical Manual of mental disorders fifth edition ((DSM-5), PCL-5). The PCL-5 score is on a scale from 0 to 80. The higher the score, the higher the level of PTSD symptoms are.', 'timeFrame': 'From inclusion to 6 months after inclusion'}
- {'measure': 'Efficacy on symptoms of Burnout', 'description': 'Change over a 6 months period in symptoms of Burnout measured by the Professional Quality Of Life questionnaire (ProQOL). The ProQOL score is on a scale from 30 to 150. The higher the score, the higher the level of Burnout symptoms are.', 'timeFrame': 'From inclusion to 6 months after inclusion'}
- {'measure': 'Efficacy on symptoms of Depression', 'description': 'Change over a 6 months period in symptoms of depression measured by the Patient Health Questionnaire (PHQ-9). The PHQ-9 score is on a scale from 0 to 27. The higher the score, the higher the level of depression symptoms are.', 'timeFrame': 'From inclusion to 6 months after inclusion'}

Please estimate the sample size based on the assumption: 
90% power with α = 0.05 (two-sided), Family Wise Type I Error Rate controlled using Holm's procedure for three primary endpoints
3.10.
        Sample size
        To reach 90% power with Î±â=â0.05 (two-sided) for a 0.245 relevant effect size maximum on each of the primary endpoints, we need, among the eligible participants, a maximum of 450 participants per trial group. This means that a maximum of 450 participants will be included in the EMDR + usual care group, and 450 participants will be allocated to the usual care group (control group). The Family Wise Type I Error Rate will be controlled using Holm's procedure to account for the presence of three primary endpoints (Holm, 1979). Therefore, it is expected that 900 participants will be recruited from the cohort for the trial. If the sample size of 900 participants included in the randomized trial is not achieved after the baseline assessment (M0), we will expand randomization at the 3-month (M3) and 6-month (M6) follow-up visits.
        The sample size of the study was primarily defined for assessing the efficacy on primary outcomes for the trial, and no formal calculations were made to determine the sample size for the cohort study. However, if 3000 participants are recruited within the cohort as expected, cohort analysis will plausibly be performed with a sufficient level of precision and power.